Visualising AI-Driven Antibody Discovery for Immunotherapy

Situation

‍AI is the industry's favourite buzzword. But for LabGenius, it’s the engine of their business. They use a smart robotic platform (EVA) to discover next-generation protein therapeutics. Entering a critical Series B fundraising round, they faced a classic biotech challenge: how do you explain a "black box" AI process to investors? They needed to prove that their machine learning approach wasn't just faster, but better at designing T-cell engagers (TCEs) that minimised off-target toxicity.

Task‍

The brief was clear but complex. We needed to visualise the invisible logic of their machine learning platform. We had to show - not just tell - how EVA evolves a molecule. The animation needed to demonstrate the critical difference between a standard antibody and a LabGenius-optimised one, specifically highlighting how their design solves the problem of off-tumour toxicity (killing cancer cells while leaving healthy tissue alone).‍

Action‍

Fusion delivered a cinematic 3D Medical Animation that bridged the gap between silicon and biology. We moved away from the standard "messy biology" look and adopted a clean, high-tech aesthetic that mirrored their brand. The animation visualised the iterative design process, showing EVA testing and refining the antibody structure. We created a clear visual metaphor for "selectivity," demonstrating the optimised TCE locking onto the tumour cells with precision while bypassing healthy cells.

Result

‍The animation became a cornerstone of their investor narrative. LabGenius successfully closed a £35 million Series B funding round, with the video playing a key role in communicating their unique value proposition. It transformed a complex abstract concept into a clear, compelling visual story that investors understood immediately.

LabGenius have gone on to feature in some high profile places. A snippet of our animation appeared in Jensen Huang’s keynote NVIDIA address at VivaTech in 2025. As well as on the CNN programme called Blueprint.

The good news doesn't stop there. Recently presented data at ESMO Immuno-Oncology 2025 shows that the approach is working.

Key findings

Key findings for LGTX-101, a highly selective Nectin-4 x CD3 T-cell engager, included:

• LGTX-101 has a highly novel 3+1 architecture designed to promote T-cell mediated cytotoxicity at the tumour site, whilst minimising activity towards healthy cells.
• The resulting avidity-driven mechanism confers >78,000-fold selectivity for killing cancer cells over healthy cells.
• In a humanised mouse model, LGTX-101 demonstrates robust in vivo efficacy, with tumour regression at 1 and 3 mg/kg across all PBMC donors, showing 89–98% tumour growth inhibition.

With both a bispecific and trispecific biologic in the pipeline as well as an ADC, we look forward to seeing the future successes yet to come from LabGenius.

If you would like Fusion Animation’s help to explain your science or concept to investors please do get in touch. We can’t promise you’ll also appear on CNN or next to Jensen Huang but you never know!

‍